These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26598236)

  • 1. Osteoprotective Effects of IL-33/ST2 Link to Osteoclast Apoptosis.
    Lima IL; Macari S; Madeira MF; Rodrigues LF; Colavite PM; Garlet GP; Soriani FM; Teixeira MM; Fukada SY; Silva TA
    Am J Pathol; 2015 Dec; 185(12):3338-48. PubMed ID: 26598236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
    Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
    J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotective Effects of Estrogen in the Maxillary Bone Depend on ERα.
    Macari S; Ajay Sharma L; Wyatt A; Knowles P; Szawka RE; Garlet GP; Grattan DR; Dias GJ; Silva TA
    J Dent Res; 2016 Jun; 95(6):689-96. PubMed ID: 26917440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo.
    Yokota K; Sato K; Miyazaki T; Kitaura H; Kayama H; Miyoshi F; Araki Y; Akiyama Y; Takeda K; Mimura T
    Arthritis Rheumatol; 2014 Jan; 66(1):121-9. PubMed ID: 24431283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis.
    Kovacić N; Lukić IK; Grcević D; Katavić V; Croucher P; Marusić A
    J Immunol; 2007 Mar; 178(6):3379-89. PubMed ID: 17339432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ST2 regulates bone loss in a site-dependent and estrogen-dependent manner.
    Macari S; Madeira MFM; Lima ILA; Pereira TSF; Dias GJ; Cirelli JA; de Molon RS; Fukada SY; Szawka RE; Garlet GP; Teixeira MM; Silva TA
    J Cell Biochem; 2018 Nov; 119(10):8511-8521. PubMed ID: 30011081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss.
    Zaiss MM; Kurowska-Stolarska M; Böhm C; Gary R; Scholtysek C; Stolarski B; Reilly J; Kerr S; Millar NL; Kamradt T; McInnes IB; Fallon PG; David JP; Liew FY; Schett G
    J Immunol; 2011 Jun; 186(11):6097-105. PubMed ID: 21515798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
    Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
    Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-1 plays an important role in the bone metabolism under physiological conditions.
    Lee YM; Fujikado N; Manaka H; Yasuda H; Iwakura Y
    Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function.
    Hill PA; Reynolds JJ; Meikle MC
    Endocrinology; 1995 Jan; 136(1):124-31. PubMed ID: 7828521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass.
    Wang L; Liu S; Zhao Y; Liu D; Liu Y; Chen C; Karray S; Shi S; Jin Y
    Cell Death Differ; 2015 Oct; 22(10):1654-64. PubMed ID: 25744024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoclast apoptosis: the role of Fas in vivo and in vitro.
    Wu X; McKenna MA; Feng X; Nagy TR; McDonald JM
    Endocrinology; 2003 Dec; 144(12):5545-55. PubMed ID: 12960091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells.
    Kitami S; Tanaka H; Kawato T; Tanabe N; Katono-Tani T; Zhang F; Suzuki N; Yonehara Y; Maeno M
    Biochimie; 2010 Apr; 92(4):398-404. PubMed ID: 20045440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spinal interleukin-33 and its receptor ST2 contribute to bone cancer-induced pain in mice.
    Zhao J; Zhang H; Liu SB; Han P; Hu S; Li Q; Wang ZF; Mao-Ying QL; Chen HM; Jiang JW; Wu GC; Mi WL; Wang YQ
    Neuroscience; 2013 Dec; 253():172-82. PubMed ID: 23988433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
    Smith R; Ransjö M; Tatarczuch L; Song SJ; Pagel C; Morrison JR; Pike RN; Mackie EJ
    J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ST2 deletion increases inflammatory bone destruction in experimentally induced periapical lesions in mice.
    Velickovic M; Pejnovic N; Mitrovic S; Radosavljevic G; Jovanovic I; Kanjevac T; Jovicic N; Lukic A
    J Endod; 2015 Mar; 41(3):369-75. PubMed ID: 25595464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of atypical chemokine receptor 2/ackr2 in bone remodeling.
    Lima ILA; Silva JMD; Rodrigues LFD; Madureira DF; Fonseca AC; Garlet GP; Teixeira MM; Russo RC; Fukada SY; Silva TAD
    Bone; 2017 Aug; 101():113-122. PubMed ID: 28476575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.